Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).

Authors

L Horn
J G Whisenant
H Wakelee
K L Reckamp
H Qiao
L Du
J Hernandez
V Huang
S N Waqar
S Patel
R E Sanborn, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
T Shaffer
K Garg
A Holzhausen
K Harrow
C Liang
L P Lim
M Li
C M Lovly

Document Type

Article

Publication Date

4-1-2019

Publication Title

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

Clinical Institute

Cancer

Department

Earle A. Chiles Research Institute

Department

Oncology

Department

Pulmonary Medicine

Recommended Citation

Horn, L; Whisenant, J G; Wakelee, H; Reckamp, K L; Qiao, H; Du, L; Hernandez, J; Huang, V; Waqar, S N; Patel, S; Sanborn, R E; Shaffer, T; Garg, K; Holzhausen, A; Harrow, K; Liang, C; Lim, L P; Li, M; and Lovly, C M, "Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)." (2019). Articles, Abstracts, and Reports. 2895.
https://digitalcommons.providence.org/publications/2895